MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

The average age of men who get diagnosed is 67.

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

Studies on whether pelvic lymph node dissection (PLND) provides a survival benefit in men with prostate cancer having surgery ...

Prostate cancer has been one of the major areas of research for radioligand therapies. Last year, Novartis officials estimated that the March 28, 2025, FDA approval for Pluvicto in metastatic ...

Prostate cancer is Australia's most commonly diagnosed cancer. One in six men will be diagnosed by the time they turn 85. Cancers are abnormal groups of cells that grow uncontrollably and start ...

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a ...

Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...

Men with early-stage prostate cancer can safely hold off on radiation or surgery , confirms a new study that offers the longest-term treatment data yet. "Watchful waiting," more recently renamed ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.